Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis

A pilot crossover study

A. Larghi, A. Crosignani, P. M. Battezzati, G. De Valle, M. Allocca, P. Invernizzi, M. Zuin, M. Podda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Results from animal studies and preliminary data from pilot studies in patients with primary biliary cirrhosis suggest that tauro-ursodeoxycholic acid has metabolic properties that may favour its long-term use as an alternative to ursodeoxycholic acid for patients with chronic cholestatic liver diseases. No direct comparison of tauro-ursodeoxycholic and ursodeoxycholic acids have yet been carried out in primary biliary cirrhosis. Methods: The effects of ursodeoxycholic and tauro-ursodeoxycholic acids were compared in 23 patients with primary biliary cirrhosis according to a crossover design. Both drugs were administered at the daily dose of 500 mg, in a randomly assigned sequence for two 6-month periods separated by a 3-month wash-out period. Results: Serum liver enzymes related to cholestasis and cytolysis consistently improved, as compared to baseline values, during the administration of both ursodeoxycholic and tauro-ursodeoxycholic acids, but no significant difference between these two bile acids was found. Both treatments were well tolerated and no patient complained of side effects. Conclusion: In the short-term, tauro-ursodeoxycholic acid appears to be safe and at least as effective as ursodeoxycholic acid for the treatment of primary biliary cirrhosis.

Original languageEnglish (US)
Pages (from-to)409-414
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Volume11
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Cross-Over Studies
Therapeutics
Cholestasis
Bile Acids and Salts
Liver Diseases
Liver
Enzymes
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Larghi, A., Crosignani, A., Battezzati, P. M., De Valle, G., Allocca, M., Invernizzi, P., ... Podda, M. (1997). Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: A pilot crossover study. Alimentary Pharmacology and Therapeutics, 11(2), 409-414.

Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis : A pilot crossover study. / Larghi, A.; Crosignani, A.; Battezzati, P. M.; De Valle, G.; Allocca, M.; Invernizzi, P.; Zuin, M.; Podda, M.

In: Alimentary Pharmacology and Therapeutics, Vol. 11, No. 2, 1997, p. 409-414.

Research output: Contribution to journalArticle

Larghi, A, Crosignani, A, Battezzati, PM, De Valle, G, Allocca, M, Invernizzi, P, Zuin, M & Podda, M 1997, 'Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: A pilot crossover study', Alimentary Pharmacology and Therapeutics, vol. 11, no. 2, pp. 409-414.
Larghi, A. ; Crosignani, A. ; Battezzati, P. M. ; De Valle, G. ; Allocca, M. ; Invernizzi, P. ; Zuin, M. ; Podda, M. / Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis : A pilot crossover study. In: Alimentary Pharmacology and Therapeutics. 1997 ; Vol. 11, No. 2. pp. 409-414.
@article{5a0c64db30d145b4bc6a6ab802fcc92a,
title = "Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: A pilot crossover study",
abstract = "Background: Results from animal studies and preliminary data from pilot studies in patients with primary biliary cirrhosis suggest that tauro-ursodeoxycholic acid has metabolic properties that may favour its long-term use as an alternative to ursodeoxycholic acid for patients with chronic cholestatic liver diseases. No direct comparison of tauro-ursodeoxycholic and ursodeoxycholic acids have yet been carried out in primary biliary cirrhosis. Methods: The effects of ursodeoxycholic and tauro-ursodeoxycholic acids were compared in 23 patients with primary biliary cirrhosis according to a crossover design. Both drugs were administered at the daily dose of 500 mg, in a randomly assigned sequence for two 6-month periods separated by a 3-month wash-out period. Results: Serum liver enzymes related to cholestasis and cytolysis consistently improved, as compared to baseline values, during the administration of both ursodeoxycholic and tauro-ursodeoxycholic acids, but no significant difference between these two bile acids was found. Both treatments were well tolerated and no patient complained of side effects. Conclusion: In the short-term, tauro-ursodeoxycholic acid appears to be safe and at least as effective as ursodeoxycholic acid for the treatment of primary biliary cirrhosis.",
author = "A. Larghi and A. Crosignani and Battezzati, {P. M.} and {De Valle}, G. and M. Allocca and P. Invernizzi and M. Zuin and M. Podda",
year = "1997",
language = "English (US)",
volume = "11",
pages = "409--414",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis

T2 - A pilot crossover study

AU - Larghi, A.

AU - Crosignani, A.

AU - Battezzati, P. M.

AU - De Valle, G.

AU - Allocca, M.

AU - Invernizzi, P.

AU - Zuin, M.

AU - Podda, M.

PY - 1997

Y1 - 1997

N2 - Background: Results from animal studies and preliminary data from pilot studies in patients with primary biliary cirrhosis suggest that tauro-ursodeoxycholic acid has metabolic properties that may favour its long-term use as an alternative to ursodeoxycholic acid for patients with chronic cholestatic liver diseases. No direct comparison of tauro-ursodeoxycholic and ursodeoxycholic acids have yet been carried out in primary biliary cirrhosis. Methods: The effects of ursodeoxycholic and tauro-ursodeoxycholic acids were compared in 23 patients with primary biliary cirrhosis according to a crossover design. Both drugs were administered at the daily dose of 500 mg, in a randomly assigned sequence for two 6-month periods separated by a 3-month wash-out period. Results: Serum liver enzymes related to cholestasis and cytolysis consistently improved, as compared to baseline values, during the administration of both ursodeoxycholic and tauro-ursodeoxycholic acids, but no significant difference between these two bile acids was found. Both treatments were well tolerated and no patient complained of side effects. Conclusion: In the short-term, tauro-ursodeoxycholic acid appears to be safe and at least as effective as ursodeoxycholic acid for the treatment of primary biliary cirrhosis.

AB - Background: Results from animal studies and preliminary data from pilot studies in patients with primary biliary cirrhosis suggest that tauro-ursodeoxycholic acid has metabolic properties that may favour its long-term use as an alternative to ursodeoxycholic acid for patients with chronic cholestatic liver diseases. No direct comparison of tauro-ursodeoxycholic and ursodeoxycholic acids have yet been carried out in primary biliary cirrhosis. Methods: The effects of ursodeoxycholic and tauro-ursodeoxycholic acids were compared in 23 patients with primary biliary cirrhosis according to a crossover design. Both drugs were administered at the daily dose of 500 mg, in a randomly assigned sequence for two 6-month periods separated by a 3-month wash-out period. Results: Serum liver enzymes related to cholestasis and cytolysis consistently improved, as compared to baseline values, during the administration of both ursodeoxycholic and tauro-ursodeoxycholic acids, but no significant difference between these two bile acids was found. Both treatments were well tolerated and no patient complained of side effects. Conclusion: In the short-term, tauro-ursodeoxycholic acid appears to be safe and at least as effective as ursodeoxycholic acid for the treatment of primary biliary cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=0030895443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030895443&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 409

EP - 414

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -